Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Lindholm

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
Circulation|November 8, 2021
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF TrialDavid D Berg, Kieran F Docherty, Naveed Sattar, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
American Heart Journal|May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVERAnkeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HFKieran F Docherty, Paul Welsh, Subodh Verma, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
Circulation|November 8, 2021
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF TrialDavid D Berg, Kieran F Docherty, Naveed Sattar, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
American Heart Journal|May 23, 2023
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVERAnkeet S Bhatt, Daniel Lindholm, Ann Nilsson, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HFKieran F Docherty, Paul Welsh, Subodh Verma, et al.
Pageof 8